MP 106 - Mycoplus
Latest Information Update: 07 Jul 2016
At a glance
- Originator Mycoplus
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 07 Jul 2016 Clinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (unspecified route) prior to July 2016